Epstein Files Act: House Votes for Transparency

The Daily Brief — Wednesday, November 19, 2025

A concise, nonpartisan roundup of notable developments from roughly the past 24 hours across the U.S., the world, science, technology, and business. Curated with a Munger‑style focus on incentives, second‑order effects, and what actually moves outcomes.

US News

  • House passes Epstein Files Transparency Act, 427–1

    • The House voted overwhelmingly to require the Justice Department to release Epstein‑related records within 30 days, with protections for victim privacy; the bill heads to the Senate amid signs some leaders may seek amendments that could stretch the timeline. (time.com)
  • Infant botulism investigation: nationwide ByHeart recall remains in effect

    • FDA/CDC continue probing a multistate cluster; as of Nov. 14, officials report 23 hospitalized infants with suspected/confirmed botulism and exposure to ByHeart formula. All unexpired ByHeart lots were recalled Nov. 11. Regulators say the brand is ~1% of U.S. formula supply. (fda.gov)

Global News

  • Russia’s largest overnight strikes in months hit Ukraine’s west; energy curbs return

    • Kyiv reports at least 19 dead and 66 injured after large‑scale missile/drone attacks targeting infrastructure, with emergency power cuts and temporary airport precautions in neighboring Poland. (reuters.com)
  • UK inflation cools into October; markets price higher odds of BoE easing

    • Headline CPI slowed, with official releases showing CPI/CPIH disinflation; data arrive days before the Nov. 26 budget and reinforce expectations of rate cuts. (ons.gov.uk)
  • After Black Sea disruption, Russia’s Novorossiysk oil loadings resume but lag

    • Export flows restarted following a Nov. 14 Ukrainian strike that briefly halted ~2% of global supply; sources say jetty damage keeps loadings 2–3 days behind schedule. (reuters.com)

Science

  • FDA clears first Arrowhead drug for a rare lipid disorder

    • Regulators approved Redemplo for familial chylomicronemia syndrome (FCS), using RNA interference against APOC3; pivotal data showed large triglyceride reductions and lower pancreatitis risk, adding to a fast‑moving field of RNA‑based medicines. (reuters.com)
  • Sentinel‑6B ocean‑height mission: fresh post‑launch updates (context)

    • Following its Nov. 16 launch, NASA highlights the satellite’s role as the new reference for global sea‑level measurement, extending a 30‑year record to guide coastal planning and weather models. (nasa.gov)

Technology

  • Microsoft leans into “agentic” AI at Ignite

    • New “Agent 365” offers an enterprise control plane to authorize/quarantine autonomous AI agents across apps; “Teams Mode” brings collaborative agent features into Microsoft 365; Microsoft details governance and context‑layer updates in its Book of News. (reuters.com)
  • AI infrastructure chessboard keeps shifting

    • OpenAI’s $38B, multi‑year AWS deal underscores the race to secure compute and diversify cloud dependencies, with capacity ramping through 2026–27. (reuters.com)

Business & Markets

  • Oil softens on inventory builds and oversupply narrative, tempered by Russia‑sanctions risk

    • Brent and WTI dipped after a U.S. stockpile rise; analysts note pending U.S. sanctions on Rosneft/Lukoil and Ukraine‑related infrastructure risks as offsets. (reuters.com)
  • Credit‑card fees settlement advances—merchant pushback continues

    • Visa and Mastercard’s revised $38B settlement would trim average swipe fees and let merchants refuse premium rewards cards; approval is up to a federal judge, and retail groups remain opposed. Practical implication: some high‑end cards could be declined at checkout. (investing.com)
  • Retail watch: Target guidance tightens; Walmart on deck

    • Target posted a sales miss and narrowed its full‑year EPS range; investors look to Walmart’s Thursday print for a read on U.S. consumer resilience. (investors.com)
  • Tonight’s catalyst: Nvidia earnings

    • The market focus is on whether data‑center growth and guidance can validate multi‑trillion‑dollar AI capex plans amid rising scrutiny of returns. (moneyweek.com)

What a Munger‑style observer might underline

  1. Process beats personalities: A discharge‑style, bipartisan supermajority forced sunlight on the Epstein records; incentive shifts can overpower partisan incentives. Watch the Senate’s amendment calculus—delay is a tell. (time.com)
  2. Bottlenecks price the world: A single Black Sea terminal’s downtime moved a multi‑trillion market and still echoes via loading backlogs—logistics fragility remains a first‑order input to energy pricing. (reuters.com)
  3. Moats need governance: As “autonomous agents” proliferate, control planes like Agent 365 aren’t features—they’re table stakes for audit, compliance, and ROI. The picks‑and‑shovels are policy as much as silicon. (reuters.com)
  4. Cash flows over narratives: AI capex requires durable customer economics; tonight’s Nvidia print is a referendum on conversion of hype into free cash flow. (moneyweek.com)
  5. Small percentages, big consequences: A 10‑basis‑point fee tweak sounds tiny, but optionality to decline premium cards could reshape rewards economics and merchant mix—second‑order effects worth modeling. (investing.com)

Time reference: Items reflect developments largely within the past 24 hours through Wednesday, November 19, 2025 (with limited context where directly market‑relevant).